^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Based on with the above results, bortezomib/lenalidomide/dexamethasone, the NCCN Panel included this regimen as a category 1, preferred option for primary treatment of transplant-eligible patients with MM. Multiple Myeloma: Maintenance therapy…Useful In Certain Circumstances…Bortezomib/lenalidomide +/- dexamethasone